Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagileridine fumarate versus sufentanil for remifentanil-induced hyperalgesia after thoracoscopic surgery
ChiCTR2500102507Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tagileridine fumarate and sufentanil in postoperative pain and opioid-induced hyperalgesia (OIH) (2 arms), sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: Pain threshold around the incision at 6 hours after surgery. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
tagileridine fumaratesufentanil
03
Conditions
postoperative painopioid-induced hyperalgesia (OIH)
Beyond the preview
Go deeper on ChiCTR2500102507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102507.